January 29, 2015 4:33 PM ET


Company Overview of kaleo, Inc.

Company Overview

kaleo, Inc., a pharmaceutical company, develops and markets personal medical products for various therapeutic areas. It offers naloxone auto-injectors for the use in case of opioid overdose; and epinephrine auto-injection used to treat allergic reactions. kaleo, Inc. was formerly known as Intelliject, Inc. and changed its name to kaleo, Inc. in January 2014. The company was incorporated in 2008 and is based in Richmond, Virginia.

111 Virginia Street

Suite 300

Richmond, VA 23219

United States

Founded in 2008





Key Executives for kaleo, Inc.

Chief Executive Officer
Co-Founder and Vice President of Product Development
Chief Financial Officer
Age: 47
Chief Operating Officer
Age: 53
Compensation as of Fiscal Year 2014.

kaleo, Inc. Key Developments

Kaléo Pharma Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM

Kaléo Pharma Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Spencer Williamson.

Kaleo Announces $150 Million Debt Financing to Support Commercialization of EVZIO(TM)

Kaleo announced that it has entered into a $150 million debt facility with PDL BioPharma to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first product (Auvi-Q(TM) in the US and Allerject(TM) in Canada) and a portion of the net sales on its second product (EVZIO(TM)). Once the note is repaid, kaleo will resume receiving 100% of all product royalties and net sales. The funds will enable kaleo to support the commercialization of EVZIO, to invest in the development of pipeline products and repay existing debt. EVZIO is intended for the emergency treatment of known or suspected opioid overdose, as manifested by life-threatening respiratory depression. Kaleo is a pioneer in life saving products that provide for peace of mind that patients can carry in their pockets. Kaleo products are designed to become part of a patient's everyday life - always there, but invisible until needed. The products are simple to use and use voice and visual cues to assist a patient through the correct drug administration process.

kaleo, Inc. - Special Call

To discuss the U.S. Food and Drug Administration approval of EVZIO for emergency treatment of opioid overdose

Similar Private Companies By Industry

Company Name Region
SGC Pharma, Inc. United States
Genetastix United States
Natural Products, LLC United States
Generics Bidco I, LLC United States
OncoSource Rx, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact kaleo, Inc., please visit www.kaleopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.